Waking Beta Cells Study

Enroll Now

Type of Study:

An interventional non-randomized trial to determine whether 8 weeks of Liraglutide or Golimumab can transiently improve beta cell function in patients with longstanding Type 1 diabetes (T1D) who secrete proinsulin and little/no C-peptide.

Title of Study:

Targeting Beta Cell Dysfunction in Longstanding T1D

Short Title:

Waking Beta Cells

Study Length: 8 weeks

Target Age/Sex: 18 – 50 years of age Male and Female


Participants will receive at no cost: study product, study materials and study-specific procedures

Link: ClinicalTrials.gov

Live better, healthier, smarter

Schedule an Appointment